Discovering Functional & Developable Bispecific Antibodies Using Fully Human Common Light Chain Transgenic Mice

Discover a groundbreaking webinar exploring innovative approaches in the discovery of bispecific antibodies using the ATX-CLC mouse strain along with reviewing case studies and validated data. Bispecific antibodies continue to be a transformative approach to treating a wide range of diseases across a range of mechanisms including T-Cell engagers, biparatopics, cis-targeting and more. However, discovering novel, developable and therapeutically relevant bispecifics is technically and strategically challenging and requires deep domain expertise as well as next-generation, integrated workflows. Alloy Therapeutic’s bispecific discovery services integrate best-in-class discovery platform technologies with world-class scientific experts to serve as an extension of research and development (R&D) teams and take bispecific programs further faster.

A number of case studies from recent campaigns will also be discussed, where the ATX-CLC platform and fully integrated bispecific antibody discovery workflow were utilized. One such campaign is where a number of binders with high specificity and affinity for Claudin 18.2 (CLDN18.2), a very challenging target with high-homology family members, were discovered. In another case, the team discovered programmed cell death-1 cluster of differentiation 28 (PD-1 X CD28) bispecifics that promoted the proliferation of exhausted clusters of differentiation 4 (CD4+) T cells and demonstrated excellent developability profiles.

Join this webinar to learn more about bispecific antibodies development and how ATX-CLC mouse strain can help enable the discovery of novel bispecific therapeutic concepts.

Speakers

Kent Bondensgaard, SVP, Head of Antibody Discovery Services, Alloy Therapeutics

Kent Bondensgaard is a skilled scientific leader with over 20 years of biologics discovery experience at Novo Nordisk and Kiniksa Pharmaceuticals, where he led high-performing teams of up to 20 scientists in developing therapeutic antibodies against 30+ targets across therapeutic areas, several of which are now in the clinic. Kent brings technical expertise in antibody discovery, screening, optimizing, and characterization including novel antibody modalities and formats, as well as insights on impact on discovery and optimization of CMC and commercial strategy. Additionally, he has extensive experience in technology and partnership due diligence, as well as resource, project, and alliance management.

Message Presenter

Jennifer Watkins-Yoon, Senior Director, Head of In Vivo Antibody Discovery, Alloy Therapeutics

Jenny Watkins-Yoon is a biologics discovery leader of 16 years with expertise in single B cell sorting, microfluidics platforms and NGS for biologics discovery, whose work has contributed to multiple IND filings. She leads immunization and binder recovery team at Alloy Therapeutics across monoclonal antibodies, as well as bispecific antibodies, TCR mimics, and cell therapies. Previously she was head of discovery biology at Hifibio Therapeutics and head of antibody discovery at Compass Therapeutics.

Message Presenter

William "Beau" Carson, Senior Director, Head of Translational Research, Alloy Therapeutics

Beau Carson is a passionate immunologist with over 16 years of experience touching on all aspects of the immune response across therapeutic areas and in both academic as well as industry research settings. Having led teams of up to 8 at Astellas Pharma and Compass Therapeutics, Beau specializes in screening in vivo and in vitro functional activity of antibody, cell therapy, and genetic medicine modalities in a broad range of disease models. He works closely with the BD team on communications, marketing, sales, and alliance management.

Message Presenter